141 related articles for article (PubMed ID: 36319039)
1. Gemcitabine-induced digital ischaemia in a patient with metastatic breast cancer.
Khan AM; Arjyal L; Shamaileh L; Simon M
BMJ Case Rep; 2022 Nov; 15(11):. PubMed ID: 36319039
[TBL] [Abstract][Full Text] [Related]
2. [A case of effective trastuzumab plus gemcitabine therapy for human epidermal growth factor receptor 2-positive breast cancer].
Yabe N; Murai S; Shimizu H; Kitasato K; Yoshikawa T; Oto I; Nakadai J; Jinno H; Kitagawa Y
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2396-8. PubMed ID: 24394124
[TBL] [Abstract][Full Text] [Related]
3. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine induced digital ischaemia and necrosis.
Holstein A; Bätge R; Egberts EH
Eur J Cancer Care (Engl); 2010 May; 19(3):408-9. PubMed ID: 19490003
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-associated digital necrosis in metastatic breast cancer.
Türkel A; Özdemir M; Kurtuluş A; Doğan M
J Oncol Pharm Pract; 2023 Oct; 29(7):1770-1775. PubMed ID: 37309162
[TBL] [Abstract][Full Text] [Related]
6. [A case of HER2-positive metastatic breast cancer responding to trastuzumab plus gemcitabine combination therapy].
Sugie T; Nagai T; Ohgaki K
Gan To Kagaku Ryoho; 2008 Apr; 35(4):683-6. PubMed ID: 18408445
[TBL] [Abstract][Full Text] [Related]
7. [Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].
Nakamura Y; Aono T; Nomura M; Iwase K; Tanaka Y
Gan To Kagaku Ryoho; 2010 Nov; 37(11):2165-8. PubMed ID: 21084819
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients?
Erten C; Demir L; Somali I; Alacacioglu A; Kucukzeybek Y; Akyol M; Can A; Dirican A; Bayoglu V; Tarhan MO
Asian Pac J Cancer Prev; 2013; 14(6):3711-7. PubMed ID: 23886170
[TBL] [Abstract][Full Text] [Related]
9. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
[TBL] [Abstract][Full Text] [Related]
10. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P
Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089
[TBL] [Abstract][Full Text] [Related]
11. A rare case of isolated adrenal metastasis of invasive ductal breast carcinoma.
Andjelić-Dekić N; Božović-Spasojević I; Milošević S; Matijašević M; Karadžić K
Srp Arh Celok Lek; 2014; 142(9-10):597-601. PubMed ID: 25518541
[TBL] [Abstract][Full Text] [Related]
12. Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients.
Sánchez-Muñoz A; Plata-Fernández Y; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Pascual J; Alba E; Sánchez-Rovira P
Clin Transl Oncol; 2014 Jun; 16(6):548-54. PubMed ID: 24085576
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial.
Iyengar NM; Smyth LM; Lake D; Gucalp A; Singh JC; Traina TA; DeFusco P; Fornier MN; Goldfarb S; Jhaveri K; Modi S; Troso-Sandoval T; Patil S; Ulaner GA; Jochelson M; Norton L; Hudis CA; Dang CT
JAMA Netw Open; 2019 Nov; 2(11):e1916211. PubMed ID: 31774522
[TBL] [Abstract][Full Text] [Related]
14. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer.
Montero A; Glück S
Case Rep Oncol; 2012 Sep; 5(3):687-92. PubMed ID: 23341813
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes.
Nelli F; Moscetti L; Natoli G; Massari A; D'Auria G; Chilelli M; Fabbri MA; Frittelli P; Ruggeri EM
Int J Clin Oncol; 2013 Apr; 18(2):343-9. PubMed ID: 22350024
[TBL] [Abstract][Full Text] [Related]
17. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
18. Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial.
Xu B; Jiang Z; Kim SB; Yu S; Feng J; Malzyner A; Del Giglio A; Chung HC; Shen LJ; Pen DL
Breast Cancer; 2011 Jul; 18(3):203-12. PubMed ID: 21465229
[TBL] [Abstract][Full Text] [Related]
19. Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer.
Curigliano G; Criscitiello C
J Clin Oncol; 2017 Aug; 35(23):2600-2603. PubMed ID: 28661760
[TBL] [Abstract][Full Text] [Related]
20. Fatal thrombotic microangiopathy after a single dose of gemcitabine as fourth-line palliative treatment for metastasized ductal breast carcinoma.
Willemsen AE; van Herpen CM; Wesseling P; Bult P; van Laarhoven HW
Acta Oncol; 2011 Apr; 50(3):462-5. PubMed ID: 20799915
[No Abstract] [Full Text] [Related]
[Next] [New Search]